CAPS® Response Letter Regarding Disruption in the Marketplace

Dear Valued Customer,

As you are aware, Amerisource Bergen has made the difficult decision to immediately cease operations of their PharMEDium business. This is an unfortunate circumstance for our industry and will be a disruptive factor for many months to come.

I want to assure you that CAPS is on solid ground and we remain committed to long term success in this industry. As an organization, we chose in 2013 to accept the challenges imposed by the Drug Quality and Security Act (DQSA) and embraced the principles of Good Manufacturing Practices (GMPs) in our 503B business. Our approach in these uncertain times remains unchanged. Of paramount importance is producing solutions of the highest quality and providing those products to you, our customers, and the patients that we jointly serve.

CAPS will continue to employ the same thoughtful business practices to serve you and your organizations, our existing customers. Safely compounding for the patients that we all serve is our number one priority. We will not alter our practices to gain market share at the expense of our patient safety imperative. We have made long term investments to expand our capacity in the 503B space and will continue to grow as we expand our highly skilled and well-trained teams.

The state of the 503B market may be unsettled today and no doubt conditions will continue to evolve over the coming weeks and months. Through this challenging time, our day to day focus will continue to be on compliance, product quality, and customer service.

Thank you for all of your support and understanding. If you should have any questions or concerns please feel free to reach out to your local Pharmacy Systems Sales Representative or our Customer Service department at 855-275-2270, option 4.


Thomas J. Wilverding, RPh, MBA
Central Admixture Pharmacy Services, Inc.